TickerFacts.

Vireo Growth Inc. (VREOF): Revenue

Annual figures by period end, from SEC filings.

$268.77M
Year ended 2025-12-31
+53.3%
3-year compound annual growth
+40.4%
5-year compound annual growth
2020-12-31: $49.21M2021-12-31: $54.45M2022-12-31: $74.63M2023-12-31: $88.13M2024-12-31: $99.38M2025-12-31: $268.77M$268.77M
2020-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$268.77M+170.4%2026-03-17, From 2025-01-01
2024-12-31$99.38M+12.8%2026-03-17, From 2024-01-01
2023-12-31$88.13M+18.1%2025-03-04, From 2023-01-01
2022-12-31$74.63M+37.1%2024-04-01, From 2022-01-01
2021-12-31$54.45M+10.6%2023-03-31, From 2021-01-01
2020-12-31$49.21Mn/a2022-03-15, From 2020-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Vireo Growth Inc. (VREOF)2025-12-31$268.77M+170.4%
Ligand Pharmaceuticals Inc (LGND)2025-12-31$268.09M+60.4%
Harrow, Inc. (HROW)2025-12-31$272.30M+36.4%
Arvinas, Inc. (ARVN)2025-12-31$262.60M-0.3%
Schrodinger, Inc. (SDGR)2025-12-31$255.87M+23.3%
Xeris Biopharma Holdings, Inc. (XERS)2025-12-31$291.85M+43.7%
Arcus Biosciences, Inc. (RCUS)2025-12-31$247.00M-4.3%
Keros Therapeutics, Inc. (KROS)2025-12-31$244.06Mn/m
Ironwood Pharmaceuticals Inc (IRWD)2025-12-31$296.15M-15.7%

Compare VREOF, LGND, HROW, ARVN side by side · Screen every company in Pharmaceutical Preparations ↗